The following stories appear in full on Today's Vidyya Medical News Service Web site.
Data from the landmark study that earned Herceptin® approval in 1998 by the Food and Drug Administration (FDA) for the treatment of metastatic breast cancer were published in the New England Journal of Medicine on 15 March 2001. The study shows that Herceptin increases overall response rate to treatment, slows progression of metastatic breast disease, and increases overall survival for patients given the drug along with standard chemotherapy compared to chemotherapy alone.
For more information: The Latest On Herceptin For Metastatic Breast Cancer
Herceptin (Trastuzumab) as a single agent is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 (human epidermal growth factor receptor2) protein and who have received one or more chemotherapy regimens for their metastatic disease. Herceptin in combination with paclitaxel is indicated for treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have not received chemotherapy for their metastatic disease. Get the full prescribing information for Herceptin in today's issue of Vidyya.
For more information: Prescribing Information: Herceptin (Trastuzumab)
Researchers from the United States, Canada and the United Kingdom are collaborating to evaluate the best treatment strategies for HIV-infected patients for whom highly active antiretroviral therapy has failed. To address the question, researchers will test new strategies for the use of medicines available to treat HIV infection. They will also test whether pauses in anti-retroviral treatment of an intended duration of three months will allow patients to recover enough from side effects to better tolerate the new therapy and whether the virus will become more sensitive to the drugs.
For more information: Researchers From The United States, Canada And The United Kingdom Seek New AIDS Strategies
Today's Vidyya articles are:
As always, we hope you enjoy the issue.